Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial
Nom du journal : J Clin Oncol
Année : 2018
Volume : 36
Page de départ : 1469
Page de fin : 1477